ENDPOINTS

PepGen delays study for Duchenne drug as it awaits safety data from another trial

PepGen is "temporarily pausing" a Phase 2 study of its exon 51 skipping drug for Duchenne muscular dystrophy, it said Tuesday. PepGen told Endpoints News via email that no patients have been enrolled in ...

Mar 4, 2025 - 17:39
 0
PepGen delays study for Duchenne drug as it awaits safety data from another trial
PepGen is "temporarily pausing" a Phase 2 study of its exon 51 skipping drug for Duchenne muscular dystrophy, it said Tuesday. PepGen told Endpoints News via email that no patients have been enrolled in ...
Read More

Tags:

Previous Article

Snakes: Facts about one of the most iconic creatures is animal hiss-tory

Next Article

At least eight drugmakers say they will participate in round two of IRA negotiat...

Related Posts

Trump’s science crackdown hits rare disease medicine: ‘We need to sit down with Elon Musk’

Trump’s science crackdown hits rare disease medicine: ‘...

Feb 28, 2025  0

BioNTech vets raise about $90M in Series A for bispecific immunology research

BioNTech vets raise about $90M in Series A for bispecif...

Feb 14, 2025  0

Biogen gets $250M in Royalty Pharma deal for lupus program

Biogen gets $250M in Royalty Pharma deal for lupus program

Feb 12, 2025  0